Core Viewpoint - The company Aide Biological (300685.SZ) plans to increase its investment in Shenzhen Sailu Medical Technology Co., Ltd. by 50 million yuan, acquiring a 2.3810% stake in the company [1] Group 1: Investment Details - Aide Biological signed a B-round capital increase agreement with Sailu Medical and its existing shareholders [1] - The investment consists of 50 million yuan in cash, with 55,701 yuan allocated as registered capital and the remainder added to Sailu Medical's capital reserve [1] Group 2: Company Profile - Sailu Medical is recognized as a national high-tech enterprise and a "specialized and innovative" small giant enterprise [1] - The company focuses on developing proprietary upstream sequencing platforms, super-resolution spatial omics platforms, and solid-phase gene chip detection platforms [1] - Sailu Medical has received several awards for its core technologies, including an excellent award at the National Disruptive Technology Innovation Competition and a gold award at the Greater Bay Area High-Value Patent Cultivation and Layout Competition [1] Group 3: Product and Technology - Sailu Medical holds over 110 authorized patents, with core products including various sequencing instruments and solutions for spatial omics and solid-phase chips [1] - The SalusPro gene sequencer is set to receive a Class III medical device registration certificate in January 2025, utilizing reversible terminator sequencing technology for DNA and RNA sequencing from human samples [1]
艾德生物:拟向赛陆医疗增资5000万元